Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 June, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Sequent Scientific Ltd

Basic Stock Data

Last Updated: June 25, 2024, 10:22 pm

Market Cap 2,986 Cr.
Current Price 120
High / Low156/86.0
Stock P/E
Book Value 26.3
Dividend Yield0.00 %
ROCE0.90 %
ROE2.46 %
Face Value 2.00
PEG Ratio0.00

Competitors of Sequent Scientific Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Suven Pharmaceuticals Ltd 18,370 Cr. 721768/42761.2 80.60.14 %21.1 %15.9 % 1.00
Pfizer Ltd 21,070 Cr. 4,6055,018/3,73138.6 7860.76 %21.9 %16.0 % 10.0
Vivimed Labs Ltd 41.0 Cr. 4.955.80/4.85 21.30.00 %51.5 %163 % 2.00
SMS Lifesciences India Ltd 242 Cr. 802948/46438.4 5850.19 %6.86 %3.66 % 10.0
Jubilant Pharmova Ltd 12,047 Cr. 756775/319295 3410.66 %6.74 %0.76 % 1.00
Industry Average15,479.50 Cr1,231.4638.85198.060.36%17.52%16.87%6.56

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales361.82320.51350.55358.05383.71341.32337.61375.31366.67333.21345.97329.36361.20
Expenses318.54300.36330.88321.83350.36339.20334.74364.96370.04341.45330.84307.11328.93
Operating Profit43.2820.1519.6736.2233.352.122.8710.35-3.37-8.2415.1322.2532.27
OPM %11.96%6.29%5.61%10.12%8.69%0.62%0.85%2.76%-0.92%-2.47%4.37%6.76%8.93%
Other Income1.592.670.743.673.77-2.320.912.86-59.86-22.729.727.28-0.71
Interest3.183.023.263.456.046.808.129.7310.8710.4812.5812.5812.44
Depreciation12.6812.5713.2112.8312.9313.9313.3813.6714.7114.2415.3615.4616.48
Profit before tax29.017.233.9423.6118.15-20.93-17.72-10.19-88.81-55.68-3.091.492.64
Tax %18.89%63.35%-250.51%21.39%45.45%26.85%74.94%4.12%-4.10%37.72%-122.65%-616.78%51.52%
Net Profit23.522.6513.8218.569.90-15.32-4.44-9.78-92.44-34.68-6.8810.681.28
EPS in Rs0.830.040.580.690.36-0.60-0.15-0.36-3.75-1.40-0.340.33-0.04

Last Updated: June 10, 2024, 4:21 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 25, 2024, 8:51 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales3273954436066848481,0391,1791,3621,4131,4211,370
Expenses3403894255506417659141,0091,1501,3031,4091,308
Operating Profit-136185643831251702121091261
OPM %-4%2%4%9%6%10%12%14%16%8%1%4%
Other Income3-5448149436910-011-58-6
Interest333443382833333624163648
Depreciation292932464041425151525662
Profit before tax-73-110-8-14-17444599413753-138-55
Tax %11%-1%-40%-19%3%3%3%13%24%15%11%46%
Net Profit-65-110-12-16-16431578210445-122-30
EPS in Rs-5.39-8.09-0.70-0.78-0.5717.301.972.813.841.65-4.86-1.44
Dividend Payout %0%0%0%0%0%1%10%0%13%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-69.23%89.09%-33.33%0.00%2793.75%-86.77%43.86%26.83%-56.73%-371.11%75.41%
Change in YoY Net Profit Growth (%)0.00%158.32%-122.42%33.33%2793.75%-2880.52%130.63%-17.03%-83.56%-314.38%446.52%

Growth

Compounded Sales Growth
10 Years:13%
5 Years:6%
3 Years:0%
TTM:-4%
Compounded Profit Growth
10 Years:5%
5 Years:%
3 Years:%
TTM:73%
Stock Price CAGR
10 Years:5%
5 Years:12%
3 Years:-24%
1 Year:34%
Return on Equity
10 Years:9%
5 Years:4%
3 Years:-2%
Last Year:-2%

Last Updated: June 25, 2024, 4:52 pm

Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital21232730484949495050505050
Reserves101601932885928599657637678642649582
Borrowings269311418473312416305325343277365444461
Other Liabilities156192159372278503380346424381378374408
Total Liabilities5475866239081,5231,8961,3321,3781,4541,3861,4351,5171,501
Fixed Assets230227238474586684476498577536564605592
CWIP64894339243318231331125535
Investments02059428428239180171833801
Other Assets253268342336485751599677693737821856872
Total Assets5475866239081,5231,8961,3321,3781,4541,3861,4351,5171,501

Reserves and Borrowings Chart

Torrent Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 21-4-45-24-0-7451161151153117
Cash from Investing Activity -65-55-81-157-310-1167-68-7210-94-65
Cash from Financing Activity 6235146179309147-57-20-43-1396732
Net Cash Flow18-2420-1-224-5280-144-16

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-324.00-412.00-455.00-256.00-373.00-222.00-200.00-173.00-65.00-256.00-432.00-427.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days737795116136111989993858889
Inventory Days173175153164165125134132139160152166
Days Payable306198147175208127141133119119107125
Cash Conversion Cycle-5954101105931109298112126132131
Working Capital Days54757997986777488106115118
ROCE %-10%-4%9%2%1%40%9%12%16%6%-3%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters53.86%53.52%53.02%53.02%52.79%52.79%52.79%52.79%52.79%52.79%52.79%52.79%
FIIs13.60%14.12%6.42%5.84%6.45%6.57%6.25%5.89%6.27%6.03%6.12%6.16%
DIIs2.49%2.03%2.13%2.04%2.27%2.79%2.81%2.92%2.92%3.23%7.23%7.59%
Public29.46%29.73%37.89%38.60%38.10%37.48%37.76%38.00%37.64%37.57%33.69%33.29%
Others0.60%0.60%0.54%0.51%0.39%0.39%0.39%0.39%0.39%0.39%0.17%0.17%
No. of Shareholders86,8481,24,0141,67,8121,91,0921,97,1761,93,9541,96,2311,91,8751,87,4741,84,5211,72,8531,66,593

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund10,788,9250.94122.72132,0972024-06-238067.43%
UTI Healthcare Fund620,3050.817.06132,0972024-06-23369.58%
Motilal Oswal Nifty Microcap 250 Index Fund132,0970.241.5132,0972024-06-230%
ITI Pharma and Healthcare Fund115,7960.921.32132,0972024-06-23-12.34%
Motilal Oswal S&P BSE Healthcare ETF1,2440.150.01132,0972024-06-23-99.06%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)-1.44-4.881.673.872.87
Diluted EPS (Rs.)-1.44-4.881.653.852.85
Cash EPS (Rs.)1.28-2.663.876.245.34
Book Value[Excl.RevalReserv]/Share (Rs.)28.5830.0429.4431.2631.71
Book Value[Incl.RevalReserv]/Share (Rs.)28.5830.0429.4431.2631.71
Revenue From Operations / Share (Rs.)54.9156.9756.8854.8247.48
PBDIT / Share (Rs.)2.900.734.848.887.26
PBIT / Share (Rs.)0.43-1.502.786.845.23
PBT / Share (Rs.)-2.19-5.522.155.503.79
Net Profit / Share (Rs.)-1.19-4.891.814.213.30
NP After MI And SOA / Share (Rs.)-1.44-4.861.663.842.81
PBDIT Margin (%)5.281.298.5116.1815.29
PBIT Margin (%)0.79-2.624.8912.4711.00
PBT Margin (%)-3.98-9.683.7710.037.97
Net Profit Margin (%)-2.16-8.583.187.676.95
NP After MI And SOA Margin (%)-2.61-8.522.917.005.92
Return on Networth / Equity (%)-5.46-17.336.0313.119.41
Return on Capital Employeed (%)1.18-3.727.4418.2212.37
Return On Assets (%)-2.32-7.922.866.854.60
Long Term Debt / Equity (X)0.210.260.170.120.20
Total Debt / Equity (X)0.680.560.460.270.38
Asset Turnover Ratio (%)0.890.170.170.200.19
Current Ratio (X)1.311.501.541.551.50
Quick Ratio (X)0.760.840.850.971.03
Inventory Turnover Ratio (X)1.770.570.740.870.93
Interest Coverage Ratio (X)1.500.517.629.045.05
Interest Coverage Ratio (Post Tax) (X)0.74-0.613.865.653.30
Enterprise Value (Cr.)3313.782217.183626.836172.312183.16
EV / Net Operating Revenue (X)2.421.562.574.531.85
EV / EBITDA (X)45.79120.8630.1628.0012.10
MarketCap / Net Operating Revenue (X)2.101.272.354.391.64
Price / BV (X)4.382.594.868.222.60
Price / Net Operating Revenue (X)2.101.272.354.391.64
EarningsYield-0.01-0.060.010.010.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 9.90

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 91.75% compared to the current price 120

Default values used*: Deafault value of 15 for Stock P/E is used

Intrinsic Value: 7.10

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 94.08% compared to the current price ₹120

Default values used*: Deafault value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -28.23%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (532.75 cr) compared to borrowings (373.08 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (275.75 cr) and profit (31.00 cr) over the years.
  1. The stock has a low average ROCE of 6.50%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 79.25, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 91.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sequent Scientific Ltd:
    1. Net Profit Margin: -2.16%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 1.18% (Industry Average ROCE: %)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -5.46% (Industry Average ROE: %)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 0.74
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.76
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✗ Stock P/E: (Industry average Stock P/E: )
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.68
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company

Sequent Scientific Ltd. is a Public Limited Listed company incorporated on 28/06/1985 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1985PLC036685 and registration number is 036685. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company’s Total Operating Revenue is Rs. 219.63 Cr. and Equity Capital is Rs. 49.67 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals301, 3rd Floor, �Dosti Pinnacle�, Plot No. E7, Road No.22, Mumbai Maharashtra 400604investorrelations@sequent.in
http://www.sequent.in
Management
NamePosition Held
Dr. Kamal K SharmaChairman & Ind.Director
Mr. Rajaram NarayananManaging Director & CEO
Mr. Sharat NarasapurJoint Managing Director
Mr. Gregory John AndrewsNon Executive Director
Mr. Neeraj BharadwajNon Executive Director
Dr. Fabian KauscheNon Executive Director
Dr.(Mrs.) Kausalya SanthanamIndependent Director
Mr. Milind SarwateIndependent Director

FAQ

What is the latest fair value of Sequent Scientific Ltd?

The latest fair value of Sequent Scientific Ltd is ₹9.90.

What is the Market Cap of Sequent Scientific Ltd?

The Market Cap of Sequent Scientific Ltd is 2,986 Cr..

What is the current Stock Price of Sequent Scientific Ltd as on 25 June 2024?

The current stock price of Sequent Scientific Ltd as on 25 June 2024 is ₹120.

What is the High / Low of Sequent Scientific Ltd stocks in FY 2024?

In FY 2024, the High / Low of Sequent Scientific Ltd stocks is 156/86.0.

What is the Stock P/E of Sequent Scientific Ltd?

The Stock P/E of Sequent Scientific Ltd is .

What is the Book Value of Sequent Scientific Ltd?

The Book Value of Sequent Scientific Ltd is 26.3.

What is the Dividend Yield of Sequent Scientific Ltd?

The Dividend Yield of Sequent Scientific Ltd is 0.00 %.

What is the ROCE of Sequent Scientific Ltd?

The ROCE of Sequent Scientific Ltd is 0.90 %.

What is the ROE of Sequent Scientific Ltd?

The ROE of Sequent Scientific Ltd is 2.46 %.

What is the Face Value of Sequent Scientific Ltd?

The Face Value of Sequent Scientific Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sequent Scientific Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE